A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease
This study tests an experimental gene therapy called AMT-130 for people with early Huntington's disease. The goal is to see if delivering a therapy directly to the brain can safely lower the harmful protein that causes nerve cells to break down over time.
You might be eligible if you are between 25 and 65 years old and have a genetic confirmation of Huntington's disease with specific gene changes. Participants must also not have certain implanted brain devices or a history of previous experimental brain surgeries.
Participants in the current group will receive a high dose of the experimental gene therapy injected directly into a deep part of the brain. The study team will closely monitor your safety, health, and how well you tolerate the treatment over time.
This study has multiple locations across the United States, including cities in Alabama, Arizona, and California. The study is currently active and ongoing, but enrollment is no longer recruiting new participants.
- 1Testing an experimental gene therapy called AMT-130 for early Huntington's disease
- 2Involves delivering treatment directly to the brain to target the disease's root cause
- 3Current study locations are active in the United States, though enrollment is closed
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.